The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 29, 2025

Filed:

Mar. 20, 2018
Applicants:

Ontario Institute for Cancer Research (Oicr), Toronto, CA;

University Health Network, Toronto, CA;

Inventors:

Shadrielle Melijah G. Espiritu, Kitchener, CA;

Yiyang Liu, Woodbridge, CA;

Paul C. Boutros, Toronto, CA;

Robert G. Bristow, Toronto, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2017.12); G16B 10/00 (2018.12); G16B 20/20 (2018.12); G16B 30/10 (2018.12); G16B 40/10 (2018.12); G16B 45/00 (2018.12); G16H 50/20 (2017.12); G16H 50/30 (2017.12); G16H 50/50 (2017.12);
U.S. Cl.
CPC ...
C12Q 1/6886 (2012.12); G16B 10/00 (2019.01); G16B 20/20 (2019.01); G16B 30/10 (2019.01); G16B 40/10 (2019.01); G16B 45/00 (2019.01); G16H 50/20 (2017.12); G16H 50/30 (2017.12); G16H 50/50 (2017.12); C12Q 2600/156 (2012.12);
Abstract

In an aspect, there is provided a method for diagnosing or prognosing a subject with cancer, the method comprising: providing cancer DNA sequencing data from a cancer sample comprising cancer DNA from the subject; comparing the cancer DNA sequencing data with control DNA sequencing data to determine genetic aberrations; determining, from the genetic aberrations, the clonal and subclonal populations present in the sample; constructing a phylogenetic map of the clonal and subclonal populations; assigning to the subject a risk level associated with a better or worse patient outcome or response to therapy; wherein a relatively higher risk level is associated with a higher level of evolution and number of subclonal populations and a relatively lower risk level is associated with a lower level of evolution and number of subclonal populations.


Find Patent Forward Citations

Loading…